Journal article
Neutralizing granulocyte/macrophage colony-stimulating factor inhibits cigarette smoke-induced lung inflammation
R Vlahos, S Bozinovski, SPJ Chan, S Ivanov, A Lindén, JA Hamilton, GP Anderson
American Journal of Respiratory and Critical Care Medicine | AMER THORACIC SOC | Published : 2010
Abstract
Rationale: Cigarette smoke is the major cause of chronic obstructive pulmonary disease (COPD), and there is currently no satisfactory therapy to treat people with COPD. We have previously shown that granulocyte/macrophage colony-stimulating factor (GM-CSF) regulates lung innate immunity to LPS through Akt/Erk activation of nuclear factor-κB and activator protein (AP)-1. Objectives: The aim of this study was to determine whether neutralization of GM-CSF can inhibit cigarette smoke-induced lung inflammation in vivo. Methods: Male BALB/c mice were exposed to cigarette smoke generated from 9 cigarettes per day for 4 days. Mice were treated intranasally with 100 μg 22E9 (anti-GM-CSF mAb) and isot..
View full abstractGrants
Funding Acknowledgements
Supported by the National Health and Medical Research Council of Australia. R.V. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.P.J.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.I. is a full-time employee of AstraZeneca R&D, Lund, Sweden. A.L. received $1,001-$5,000 from GlaxoSmithKline Sweden in advisory board fees, $1,001-$5,000 from AstraZeneca Sweden in lecture fees, and has private ownership of a non-provisional U.S. patent application (unrelated area). J.A.H. received $1,001-$5,000 from MorphoSys AG in consultancy fees, more than $100,001 from MorphoSys AG in royalties (licensing fees and milestone payments made), and holds a patent from MorphoSys. J.A.H's employer, the University of Melbourne, has licensed patented technology. G.P.A. received $1,001-$5,000 from MorphoSys AG in consultancy fees and more than $100,001 from MorphoSys AG in royalties. Licensing fees and Milestone payments made to the University of Melbourne by MorphoSys AG in relation to GM-CSF technology. G.P.A.'s employer, the University of Melbourne, has licensed patented technology relating to therapeutically targeting GM-CSF to MorphoSys AG, Germany. Licensing fees and milestone payments made to the University of Melbourne by MorphoSys AG in relation to GM-CSF technology were in the $100,001 or more dollar range.